These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 2980086)

  • 21. [Serum CA 15.3-ELSA in non-tumor pathology].
    Ruibal A; Genollá J; Rosell M; Moragas G
    Med Clin (Barc); 1987 Mar; 88(11):476. PubMed ID: 3472024
    [No Abstract]   [Full Text] [Related]  

  • 22. Erythrocyte T-activation: clinical importance & recognition by a simple routine technique.
    Sethi S; Dhingra N; Madan N; Sood SK
    Indian J Pathol Microbiol; 1994 Jan; 37(1):109-11. PubMed ID: 8088895
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Study of the Thomsen-Friedenreich antigen in bladder tumors].
    Fukatsu H; Yamada H; Nonomura H; Miyagawa Y; Waki M; Hatano Y; Hiraiwa S; Muramatsu T; Nishikawa E; Yamada Y
    Hinyokika Kiyo; 1988 Feb; 34(2):260-7. PubMed ID: 3376818
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thomsen-Friedenreich and PK antigens in pig-to-human xenotransplantation.
    Cairns T; Lee J; Goldberg LC; Hakim N; Cook T; Rydberg L; Samuelsson B; Taube D
    Transplant Proc; 1996 Apr; 28(2):795-6. PubMed ID: 8623404
    [No Abstract]   [Full Text] [Related]  

  • 25. [Tn syndrome].
    Tanaka T; Ueki J
    Ryoikibetsu Shokogun Shirizu; 1998; (22 Pt 3):582-4. PubMed ID: 9851223
    [No Abstract]   [Full Text] [Related]  

  • 26. Preliminary results on the use of Ca 15-3 in malignant ovarian pathology.
    Ferdeghini M; Gadducci A; Romagnoli S; Bartolini T; Facchini V; Scatena P; Bianchi R; Fioretti P
    J Nucl Med Allied Sci; 1987; 31(4):299-302. PubMed ID: 3481812
    [No Abstract]   [Full Text] [Related]  

  • 27. [Thomsen antigen in human normal and tumor tissues].
    Berdinskikh MS; Pavliuchenkova RP; Kiseleva AS; Kulakova AM; Kosiakov PN
    Biull Eksp Biol Med; 1983 Mar; 95(3):59-61. PubMed ID: 6830988
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risks associated with blood transfusion in newborn infants.
    Blajchman MA; Sheridan D; Rawls WE
    Clin Perinatol; 1984 Jun; 11(2):403-15. PubMed ID: 6086206
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Correlation between the levels of CA 19-9 and Ca-50 in colorectal cancer].
    Lamíquiz Vallejo A; Domínguez Merru-Urrutia MJ; Loizate Totoricagüena A; Cruz Fombellida Cortázar J
    Med Clin (Barc); 1988 Jan; 90(1):42. PubMed ID: 3162290
    [No Abstract]   [Full Text] [Related]  

  • 30. Differential requirement for a cellular type-1 immune response in tumor-associated versus alloantigen-targeted GvT effects.
    Stelljes M; Specht C; Albring J; Volkmann S; Schlösser V; Pauels HG; Poremba C; Bisping G; Opitz C; Scheffold C; Silling G; Kiehl M; Berdel WE; Kienast J
    Transplantation; 2007 Feb; 83(3):314-22. PubMed ID: 17297406
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Introduction of a new laboratory marker for cancer of the pancreas (CA 19.9). Current experience].
    Nunes AP; Jukemura J; Machado MC; Scheinberg MA
    Rev Paul Med; 1986; 104(2):99-101. PubMed ID: 3468583
    [No Abstract]   [Full Text] [Related]  

  • 32. [Isomerization of trifluoroacetamidopropyl-2-acetamido-2-deoxy-D- galactopyranoside into alpha-anomer. A convenient method of synthesis of the artificial T-antigen].
    Bovin NV; Zemlianukhina TV; Khorlin AIa
    Bioorg Khim; 1986 Apr; 12(4):533-8. PubMed ID: 3718549
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Significance of a new tumor marker (CA 19-9) in the differential diagnosis of pathological changes in the pancreas detected by ultrasonic diagnosis].
    Bohár L; Szilvási I; Bodorné N; Varsányi N; Barda L; Sarkadi G
    Orv Hetil; 1985 Oct; 126(41):2525-7. PubMed ID: 3900874
    [No Abstract]   [Full Text] [Related]  

  • 34. [The tumor-associated antigen CA 19-9 in the differential diagnosis and course control of malignancies of the pancreas and the gastrointestinal tract].
    Klapdor R; Greten H
    Dtsch Med Wochenschr; 1984 Dec; 109(50):1935-9. PubMed ID: 6210188
    [No Abstract]   [Full Text] [Related]  

  • 35. Reduced acute phase response to differentiate between viral and bacterial infections in children.
    Urbach J; Rotstein R; Fusman R; Zeltser D; Shapira I; Branski D; Berliner S
    Pediatr Pathol Mol Med; 2002; 21(6):557-67. PubMed ID: 12537773
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Significance of CA-125 antigen in the monitoring of therapy and clinical course of ovarian cancer].
    Pulay T; Csömör S
    Orv Hetil; 1987 Dec; 128(50):2615-9. PubMed ID: 3323994
    [No Abstract]   [Full Text] [Related]  

  • 37. [Human breast cancer markers].
    Remennik LV
    Eksp Onkol; 1985; 7(4):3-8. PubMed ID: 2994992
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glycan bioengineering in immunogen design for tumor T antigen immunotargeting.
    Sendra VG; Zlocowski N; Ditamo Y; Copioli S; Tarp MP; Bennett EP; Clausen H; Roth GA; Nores GA; Irazoqui FJ
    Mol Immunol; 2009 Oct; 46(16):3445-53. PubMed ID: 19726087
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Diagnosis of pancreatic carcinoma using 2 associated monoclonal antibodies].
    Yao CZ; Zeng XJ; Wang SZ
    Zhonghua Wai Ke Za Zhi; 1987 Nov; 25(11):655-8, 670. PubMed ID: 3482539
    [No Abstract]   [Full Text] [Related]  

  • 40. [Biological significance of tumor marker].
    Ochi Y
    Rinsho Byori; 1985 Aug; 33(8):831-8. PubMed ID: 3908745
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.